Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026)
Zymeworks' (ZYME) quarterly Non-Current Deferred Tax Liability came in at $3.8 million in Q1 2026, down 20.52% year-on-year from $4.8 million in Q1 2025, and down 36.51% quarter-over-quarter from $6.0 million in Q4 2025.
Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Non-Current Deferred Tax Liability across 6 years of filings, most recently posting $3.8 million for Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $3.8 million, down 20.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 million (down 20.52% YoY), and the FY2025 annual result was $6.0 million, up 26.61% from the prior year.
- Non-Current Deferred Tax Liability came in at $3.8 million for Q1 2026 at Zymeworks, down from $6.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $6.0 million in Q4 2025 to a low of $1.6 million in Q3 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $3.4 million (2024), against an average of $3.4 million.
- Across the five-year window, Non-Current Deferred Tax Liability plunged 87.32% in 2022 and jumped 84.56% in 2023, its largest moves.
- Zymeworks' Non-Current Deferred Tax Liability stood at $1.8 million in 2022, then surged by 84.56% to $3.3 million in 2023, then soared by 44.27% to $4.8 million in 2024, then rose by 26.61% to $6.0 million in 2025, then slumped by 36.51% to $3.8 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $3.8 million (Q1 2026), $6.0 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Zymeworks | 1.71 Bn | 1.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.83 Mn |
| Mar 31, 2026 | 3.83 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 4.82 Mn |
| Mar 31, 2025 | 4.82 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 3.30 Mn |
| Dec 31, 2023 | 3.30 Mn |